WO2024175020 - ANTI-IL2RA ANTIBODIES AND USES THEREOF

National phase entry:
Publication Number WO/2024/175020
Publication Date 29.08.2024
International Application No. PCT/CN2024/077898
International Filing Date 21.02.2024
Title **
[English] ANTI-IL2RA ANTIBODIES AND USES THEREOF
[French] ANTICORPS ANTI-IL2RA ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park Daxing District, Beijing 102600, CN
Inventors
YANG, Yongfei No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park Daxing District, Beijing 102600, CN
ZHANG, Wenjiao No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park Daxing District, Beijing 102600, CN
CAO, Shuzhen No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park Daxing District, Beijing 102600, CN
GUAN, Zeliang No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park Daxing District, Beijing 102600, CN
ZHANG, Jing No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park Daxing District, Beijing 102600, CN
LIU, Yacui No.12 Baoshen South Street, Daxing Bio-Medicine Industry Park Daxing District, Beijing 102600, CN
Priority Data
PCT/CN2023/077623   22.02.2023   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing2615
EPO Filing, Examination27085
Japan Filing598
South Korea Filing575
USA Filing, Examination17510
MasterCard Visa

Total: 48,383

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] Provided are anti-IL2RA (interleukin-2 receptor alpha chain) antibodies, antigen-binding fragments, and the uses thereof.[French] L'invention concerne des anticorps anti-IL2RA (chaîne alpha du récepteur de l'interleukine-2), des fragments de liaison à l'antigène et leurs utilisations.